GET DAILY SIGNALSCabaletta Bio (CABA): Weighing the $13 Consensus Target and a Potential +770% Move
Key Takeaways
- The central $13 price target is the arithmetic mean of eight individually verified analyst price targets, spanning a wide range of $3 to $30.
- With shares near $1.50, reaching $13 would require a roughly 770% gain, an exceptionally large move even for a clinical-stage biotech.
- Bullish analysts cite durable, immunomodulator-free responses for lead CAR-T candidate rese-cel in autoimmune diseases; cautious analysts reflect financing and binary clinical-trial risk.
- The pivotal myositis data readout, expected in the second half of 2027, is the single most important catalyst ahead of a planned Biologics License Application (BLA) in early 2028.
- The biggest risks are clinical failure, further share dilution, and the years of pre-revenue, cash-burning development still ahead.
- For more context, explore Major News, Today's Price Move, the Forecast, and Earnings pages.
- For additional AI-driven ideas, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Cabaletta Bio, Inc. (CABA) is a clinical-stage biotechnology company developing engineered CAR T cell therapies for autoimmune diseases, led by its lead candidate rese-cel. Because the company has no approved products or revenue, analysts build their targets almost entirely on the probability of future clinical and regulatory success rather than on earnings multiples.
Eight individually attributable price targets were reviewed. They range from a low of $3 (Wells Fargo, Equal-Weight) and $4 (Evercore ISI, Hold) to a high of $30 (Cantor Fitzgerald, Buy). In between sit Morgan Stanley at $13, Jefferies at $14, H.C. Wainwright and Guggenheim each at $16, and Citi at $8 after trimming its prior $10 target following the third-quarter report. The arithmetic mean of these eight targets is roughly $13, which serves as the central target here. The dispersion from $3 to $30 reflects a genuinely binary outlook: a de-risked, multi-indication cell-therapy franchise is worth far more than a candidate that stumbles in pivotal trials. To cross-check how CABA stacks up against peers, I also checked this using Tickeron’s AI Screener.
Current Market Position and Path Toward the Target
Shares closed near $1.50, up sharply on fresh Phase 1/2 data presented at the American College of Rheumatology (ACR) 2026 meeting. At that price, reaching the $13 central target would require an increase of roughly 770%, which by any standard is a very large move. Cabaletta's market capitalization is only about $320 million, so the target is not an aggressive absolute figure for a company aiming at a blockbuster autoimmune franchise, but the gap reflects both clinical uncertainty and the company's pre-revenue status.
The path runs almost entirely through clinical data. Rese-cel, a fully human CD19-directed CAR T therapy designed to "reset" the immune system with a single infusion, has shown durable, immunomodulator-free responses across dermatomyositis, lupus nephritis, and systemic sclerosis. Management expects registrational topline results in myositis in the second half of 2027, with a BLA submission in the first quarter of 2028.
What Could Support a Move Toward the Target
- Compelling durability data: at ACR 2026, all six dermatomyositis patients maintained moderate-to-major responses off immunomodulators through one year, and all five biopsied lupus nephritis patients achieved remission with histologic response.
- A favorable safety profile across 71 patients, with the large majority experiencing no or Grade 1 cytokine release syndrome and no severe neurotoxicity events.
- A strengthened balance sheet, with roughly $299 million in cash reported as of September 30, 2026, and a removed going-concern warning.
- Strategic backing, including a 10-year manufacturing agreement with Cellares and a prior $150 million financing that drew participation from Eli Lilly and leading life-science funds.
What Could Prevent the Target From Being Reached
- Clinical risk is paramount: pivotal myositis results are not due until the second half of 2027, and negative or mixed data would undermine the entire valuation case.
- Ongoing cash burn, with a third-quarter net loss of about $53 million and no revenue, creates recurring dilution risk despite the current cash runway into 2028.
- The shares have been volatile, including a sharp October decline tied to warrant-driven dilution concerns and financing overhang.
- Regulatory and manufacturing execution for a cell therapy must still be proven at commercial scale before any revenue arrives.
Technical Levels and Market Structure
CABA trades near the lower end of its 52-week range of roughly $1.18 to $4.23 and below its 50-day and 200-day moving averages, reflecting the recent sell-off before the ACR data. The psychological $1 level and the $1.18 52-week low mark the key downside reference points, while the $4.23 52-week high stands as distant overhead resistance. A durable move above the recent $1.30–$1.55 consolidation zone would be an early sign of improving trend structure. I also checked recent patterns here with Tickeron’s AI Pattern Search Engine for additional context.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though for a clinical-stage biotech the relevant catalysts extend well beyond that window. The pivotal RESET-Myositis topline results, guided to the second half of 2027, and the subsequent BLA submission planned for early 2028 are the decisive events. Nearer term, investors should watch further data presentations, analyst target revisions, quarterly cash and R&D spending, any additional financing announcements, and updates on the systemic sclerosis registrational cohort.
Final Assessment
The $13 central target is the average of eight verified analyst price targets ranging from $3 to $30, and it sits roughly 770% above the recent share price — a very large required move. Supporters point to durable, immunomodulator-free efficacy and a clean safety profile that could justify a premium if pivotal trials succeed, while skeptics emphasize the binary nature of the 2027 readout, ongoing cash burn, and dilution risk. The wide target range itself signals genuine disagreement about how much of the future value is already de-risked. Whether CABA approaches $13 ultimately hinges on pivotal clinical data and regulatory execution rather than near-term price action, making the second-half-2027 myositis results the key event to monitor.
Exploring AI Daily Buy/Sell Signals for Biotech Volatility
In my own work, I find Tickeron’s AI Daily Buy/Sell Signals particularly useful for names like CABA where sentiment shifts quickly around data readouts. The tool scans thousands of stocks and ETFs in real time, highlighting potential Buy, Sell, or Hold opportunities based on technical and market factors. It helps me stay on top of trend changes without replacing my own due diligence, and I often cross-reference it when clinical catalysts are on the horizon.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for CABA turns negative, indicating new downward trend
CABA saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned negative. In 82 of the 91 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CABA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CABA entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CABA's RSI Indicator exited the oversold zone, 24 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for CABA just turned positive on October 22, 2026. Looking at past instances where CABA's MACD turned positive, the stock continued to rise in 44 of 49 cases over the following month. The odds of a continued upward trend are 90%.
Following a +8.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where CABA advanced for three days, in 218 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
CABA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.047) is normal, around the industry mean (3.498). P/E Ratio (-0.942) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. CABA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CABA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases
Industry Biotechnology
Advertisement